All In Biotech

NDA 020805 · Sandoz

Cipro Hc

Ciprofloxacin Hydrochloride, Hydrocortisone · Otic · Corticosteroid

Last checked: Nov 20, 2026Latest source record: Mar 20, 2017 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1998

Feb 10, 1998

Approved uses

1

Original approval plus efficacy supplements

Registered trials

364

90 Phase 3, 32 recruiting

FAERS reports

20,745

13,575 serious, 1,437 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect May 29, 2026.

INDICATIONS AND USAGE Ciprofloxacin hydrochloride and hydrocortisone otic suspension is indicated for the treatment of acute otitis externa in adult and pediatric patients, one year and older, due to susceptible strains of Pseudomonas aeruginosa , Staphylococcus aureus , and Proteus mirabilis .

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • CIPRO HC · CIPROFLOXACIN HYDROCHLORIDE EQ 0.2% BASE; HYDROCORTISONE 1% · SUSPENSION/DROPS, OTIC · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Ciprofloxacin" as an intervention, any sponsor and status, largest first.

All 364 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug hypersensitivity2,484
  • pain1,607
  • neuropathy peripheral1,445
  • nausea1,413
  • diarrhoea1,408
  • arthralgia1,388
  • fatigue1,329
  • urinary tract infection1,024
  • dyspnoea991
  • pain in extremity986
  • headache985
  • drug ineffective926

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004331
2005401
2006457
2007319
2008792
2009659
2010710
2011685
2012622
20131,034
20141,211
20151,694
20162,846
20171,533
20181,484
20191,842
20201,248
2021870
2022532
2023476
2024380
2025404
2026215

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

  • To Be Discontinued · updated Oct 30, 2026

    Cipro, Otic Suspension/Drops, 0.2% base, 1% (NDC 66758-087-70). Discontinuation of the manufacturing of NDC 66758-087-70. Authorized generic is available under new NDC 0781-6218-70

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Cipro HC (Ciprofloxacin/Hydrocortisone)

2024 spending

$3.7M

Beneficiaries

9,059

10,023 claims

Per beneficiary

$410

$36.56 per unit

View as table
YearSpending
2020$0
2021$0
2022$1,234,454
2023$3,131,907
2024$3,712,181

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,835 on PubMed

Sponsor: Novartis

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.